511 related articles for article (PubMed ID: 26489444)
1. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
Wagstaff J; Jones R; Hawkins R; Porfiri E; Pickering L; Bahl A; Brown J; Buchan S
Ann Oncol; 2016 Jan; 27(1):159-65. PubMed ID: 26489444
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
5. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
[TBL] [Abstract][Full Text] [Related]
6. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Rixe O; Oudard S; Negrier S; Szczylik C; Kim ST; Chen I; Bycott PW; Baum CM; Figlin RA
N Engl J Med; 2007 Jan; 356(2):115-24. PubMed ID: 17215529
[TBL] [Abstract][Full Text] [Related]
8. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
Ravaud A; Oudard S; De Fromont M; Chevreau C; Gravis G; Zanetta S; Theodore C; Jimenez M; Sevin E; Laguerre B; Rolland F; Ouali M; Culine S; Escudier B
Ann Oncol; 2015 Jun; 26(6):1123-1128. PubMed ID: 25802238
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
Hawkins R; Fife K; Hurst M; Wang M; Naicker N; Nolasco S; Eisen T; Matakidou A; Gordon J
BMC Cancer; 2020 Jul; 20(1):670. PubMed ID: 32680483
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
Kalra S; Atkinson BJ; Matrana MR; Matin SF; Wood CG; Karam JA; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
BJU Int; 2016 May; 117(5):761-5. PubMed ID: 26032863
[TBL] [Abstract][Full Text] [Related]
15. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
Izzedine H; Derosa L; Le Teuff G; Albiges L; Escudier B
Ann Oncol; 2015 Jun; 26(6):1128-1133. PubMed ID: 25795198
[TBL] [Abstract][Full Text] [Related]
16. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Oudard S; Negrier S; Szczylik C; Pili R; Bjarnason GA; Garcia-del-Muro X; Sosman JA; Solska E; Wilding G; Thompson JA; Kim ST; Chen I; Huang X; Figlin RA
J Clin Oncol; 2009 Aug; 27(22):3584-90. PubMed ID: 19487381
[TBL] [Abstract][Full Text] [Related]
17. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Buchler T; Poprach A; Bortlicek Z; Lakomy R; Chloupková R; Vyzula R; Zemanova M; Kopeckova K; Svoboda M; Slaby O; Kiss I; Studentova H; Hornova J; Fiala O; Kopecky J; Finek J; Dusek L; Melichar B;
Clin Genitourin Cancer; 2017 Dec; 15(6):e1047-e1053. PubMed ID: 28720439
[TBL] [Abstract][Full Text] [Related]
20. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]